Introduction
============

Gastric cancer (GC) is the third leading cause of cancer mortality worldwide, although the incidence in some areas has decreased.[@b1-ott-9-5975],[@b2-ott-9-5975] Since most patients are diagnosed at advanced stages with limited treatment approaches, GC continues to exhibit a serious health burden. The contributing factors for GC are complicated and not entirely clear. Cumulative evidence has shown that apart from environmental risk factors, genetic factors are also important for the development and progression of GC.[@b3-ott-9-5975] Moreover, our previous studies have revealed the significant association of polymorphisms in H19, miR-34b/c, JAK2, and RAGE with the susceptibility to gastric carcinogenesis.[@b4-ott-9-5975]--[@b7-ott-9-5975]

As a member of DACT family, disheveled-binding antagonist of beta-catenin 1 (*DACT1*) plays an important role in regulating the planar cell polarity (PCP) pathway.[@b8-ott-9-5975]--[@b10-ott-9-5975] PCP pathway, a significant branch of noncanonical Wnt signaling, is activated through the binding of noncanonical Wnt proteins to transmembrane receptors (Frizzled), which results in recruiting cytoplasmic disheveled (Dvl) to the plasma membrane. The PCP pathway affects various cellular processes and plays a significant role in the process of carcinogenesis.[@b11-ott-9-5975] Increasing evidence has shown that *DACT1* is associated with several human malignancies, such as GC,[@b12-ott-9-5975] breast cancer,[@b13-ott-9-5975] liver cancer,[@b14-ott-9-5975] lung cancer,[@b15-ott-9-5975] and colorectal cancer.[@b16-ott-9-5975] As to GC, *DACT1* is a functional antioncogene that is mainly deactivated by promoter methylation. *DACT1* may inhibit nuclear factor kappa B (NF-κB) signaling pathway and thus suppresses tumorigenesis by promoting cell apoptosis and decreasing cell proliferation.[@b12-ott-9-5975] However, the associations of genetic variants in the *DACT1* with risk in malignant diseases have not been reported before, including GC.

In this research, we suggested that single-nucleotide polymorphisms (SNPs) in *DACT1* gene were likely to impact the susceptibility to GC. To certify this, we focused on three *DACT1* tag SNPs (rs863091, rs17832998, and rs167481) in a case--control study of 602 patients with GC and 602 healthy controls from the Chinese Han population. Furthermore, we studied the role of the risk-associated polymorphism in regulating its messenger RNA (mRNA) expression in GC tissues and normal tissues, in order to further explore its potential regulation mechanism in adjusting disease risk.

Subjects and methods
====================

Subjects
--------

This hospital-based case--control study consisted of 602 patients diagnosed with GC and 602 noncancer controls. All patients were successively enrolled with newly diagnosed, histopathologically confirmed GC in the First Affiliated Hospital of Nanjing Medical University between 2009 and 2015. The patients without previous history of cancer or previous chemotherapy or radiotherapy participated in our study. As a control group, all age- and sex-matched subjects without self-reported history of malignancies or precancerous condition of GC were randomly recruited from the Department of General Surgery in the same regions during the same period. The control group mainly suffered from varicose veins, aneurysm, hernia, and abdominal trauma. All subjects with no genetic relationship in this study were ethnic Han Chinese from Jiangsu Province or its circumjacent areas. After signing the written informed consent, each patient donated a 5 mL venous blood sample. Subjects' data including age, sex, diabetes, hypertension, smoking history, and residence were collected by a standard questionnaire.

Subjects were considered as smokers if they previously or currently smoked ≥10 cigarettes per day for at least 2 years. Individuals who had sustained systolic blood pressure \>140 mmHg and diastolic blood pressure \>90 mmHg and/or were presently receiving antihypertensive treatment were considered as hypertensive. Subjects were considered as diabetic if they had a fasting plasma glucose ≥7 mmol/L or random plasma glucose ≥11 mmol/L and with typical symptoms of hyperglycemia (polyuria, polydipsia, and weight loss) or requiring insulin or oral hypoglycemic agents. Rural or urban residence was determined by a questionnaire according to the addresses and data of the subjects collected. The Ethics Committee of the First Affiliated Hospital of Nanjing Medical University approved this study, and written informed consent was obtained from each participant before sample collection.

SNP selection
-------------

We obtained genotype data for Han Chinese within *DACT1* released by HapMap public database (HapMap Data Rel 27 Phase II + III, Feb09, on NCBI B36 assembly, dbSNP b126) and used the Haploview program (Broad Institute, Cambridge, MA, USA) to choose the tag SNPs with *r*^2^ (linkage disequilibrium correlation coefficient) \>0.8 and minor allele frequency ≥0.05. As a result, three tag SNPs were chosen in the present research: rs863091, rs17832998, and rs167481.

Genotyping
----------

As described in our previous study, reference techniques were used to extract genomic DNA from peripheral blood leukocytes.[@b17-ott-9-5975] TaqMan-MGB method (Thermo Fisher Scientific, Waltham, MA, USA) was used to acquire all the genotypes of the three SNPs (ie, rs863091, rs17832998, and rs167481). The sequences of the probes and primers used in genotyping are summed up in [Table 1](#t1-ott-9-5975){ref-type="table"}. Utilization of 5 µL 2× TaqMan Genotyping Master Mix, 0.125 µL probes, 0.25 µL primers, 10 ng genomic DNA, and 2.5 µL double distilled water composed the 10 µL reaction mixture. Amplification was performed at 95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. In accordance with the manufacturer's instructions, the 96-well ABI StepOnePlus Real-Time PCR System (Thermo Fisher Scientific) was used to conduct the amplifications, and allelic discrimination was performed using Stepone v2.2.2 software (Thermo Fisher Scientific). In order to do quality control, each reaction plate contained two positive experimental controls with known genotype and two negative experimental controls (water).[@b4-ott-9-5975] The call rate for each SNP was 100%. Additionally, a random number of \~10% of the samples were subjected to repeated assays by a different person, and the repeatability was 100%.

Real-time polymerase chain reaction analysis of *DACT1*
-------------------------------------------------------

*DACT1* mRNA expression levels were analyzed by quantitative reverse transcription--polymerase chain reaction (PCR) using total RNA extracted from 76 pairs of cancerous and normal gastric tissue samples using Trizol reagent (Thermo Fisher Scientific). Total RNA was reversely transcribed to first-strand complementary DNA using Primescript RT Reagent (Takara, Otsu, Japan). The real-time PCR primers for *DACT1* were as follows: forward primer 5′-TGTGAATCCCAAGTACCAGTGT-3′ and reverse primer 5′-CCGTCAGACAAAGGAGAAACATT-3′. β-Actin was used to normalize *DACT1* gene expression levels and amplified with forward primer 5′-AGAAAATCTGGCACCACACC-3′ and reverse primer 5′-TAGCACAGCCTGGATAGCAA-3′. Amplification reactions were executed in a 10 µL reaction volume containing 0.2 µL primers, 5 µL Master mix, and 100 ng complementary DNA. The cycling conditions were set at 95°C for 5 minutes, followed by 40 cycles at 95°C for 10 seconds and 60°C for 30 seconds. Real-time PCR was carried out using FastStart Universal SYBR-Green Master (Vazyme, Nanjing, People's Republic of China) with the StepOnePlus Real-Time PCR System in triplicate. The 2^−ΔCT^ algorithm was used for calculating the expression of individual *DACT1* relative to expression of β-actin.[@b4-ott-9-5975]

Statistical analysis
--------------------

Differences in genotype frequencies of the three SNPs between cases and controls and demographic characteristics were calculated using Pearson's *χ*^2^ tests (for categorical variables) and Student's *t*-test (for continuous variables). The Mann--Whitney rank sum test was used to analyze the quantitative variables departing from the normal distribution. The Hardy--Weinberg equilibrium was assessed for controls using the goodness-of-*χ*^2^ test. Associations between the genotypes and alleles and risk of GC were estimated by odds ratios (ORs) and 95% confidence intervals (CIs). Woolf approximation method was used to compute the crude OR, and the unconditional logistic regression method was used to assess adjusted OR, with adjustments for age, sex, hypertension, diabetes, smoking status, and residence. We used the SPSS Version 22.0 (IBM Corporation, Armonk, NY, USA) to perform statistical analyses. All *P*-values in our study were two-sided, and *P*\<0.05 was considered as significant.

Results
=======

Characteristics of the study subjects
-------------------------------------

A total of 602 GC cases and 602 controls were recruited in this study. The baseline characteristics of GC cases and controls are presented in [Table 2](#t2-ott-9-5975){ref-type="table"}. No significant differences between GC cases and cancer-free controls regarding age and sex (*P*=0.087 and 0.067) were found, which indicated that the frequency matching was adequate. The mean age was 60.6±10.7 years for cancer patients and 59.5±12.9 years for controls, respectively. There was no significant difference in distributions of hypertension, diabetes, and residence between cases and controls. The only exception was that smoking was more frequently distributed among patients with GC than controls.

Associations of *DACT1* tag SNPs and GC risk
--------------------------------------------

[Table 3](#t3-ott-9-5975){ref-type="table"} presents the association between the genotype of *DACT1* SNPs and risk of GC. In the controls, all observed genotype frequencies were in accordance with the Hardy--Weinberg equilibrium (*P*=0.055 for rs863091, *P*=0.404 for rs17832998, and *P*=0.659 for rs167481). To our data, we found that SNP rs863091 was associated with GC risk. In SNP rs863091, the T allele frequency was obviously lower in the case group (12.2%; T vs C: *P*=0.007, adjusted OR =0.72, 95% CI =0.58--0.91) than the control group (16.1%). Compared with the CC genotype, the genotypes TT and (CT + TT) were associated with a significantly decreased risk of GC (TT vs CC: *P*=0.009, adjusted OR =0.34, 95% CI =0.15--0.77; CT + TT vs CC: *P*=0.030, adjusted OR =0.74, 95% CI =0.57--0.97) after adjustment for age, sex, smoking status, residence, hypertension, and diabetes. However, no significant association with GC risk was observed in SNP rs17832998 or rs167481.

The genotype--phenotype correlation between rs863091 and *DACT1* expression
---------------------------------------------------------------------------

In order to investigate the genotype--phenotype correlation between rs863091 and *DACT1* expression, we further analyzed the *DACT1* mRNA expression levels in 76 pairs of GC and normal tissue samples with different genotypes. As illustrated in [Figure 1A](#f1-ott-9-5975){ref-type="fig"}, compared with the CC genotypes (0.10±0.12 \[n=47\]), the relative *DACT1* mRNA expression levels in samples with CT (0.21±0.18 \[n=25\]), TT (0.28±0.16 \[n=4\]), and CT + TT (0.22±0.17 \[n=29\]) genotypes were significantly higher (*P*\<0.05, *P*\<0.01, and *P*\<0.05, respectively) in GC tissue specimens. However, as to the relative *DACT1* mRNA expression levels in normal tissue samples, no significant differences between CC (0.10±0.12 \[n=47\]) and CT (0.08±0.07 \[n=25\]), TT (0.10±0.07 \[n=4\]), or CT + TT (0.09±0.07 \[n=29\]) genotypes of the rs863091 were found ([Figure 1B](#f1-ott-9-5975){ref-type="fig"}). We did not investigate the allele-specific effect of rs17832998 and rs167481 on *DACT1*, because their associations with GC risk were not observed.

Stratified analysis of polymorphism and GC risk
-----------------------------------------------

We conducted stratified analyses for *DACT1* rs863091, rs17832998, and rs167481 polymorphisms based on age, sex, smoking, and residence status, which may have potential influence on genetic effect ([Tables 4](#t4-ott-9-5975){ref-type="table"}[](#t5-ott-9-5975){ref-type="table"}--[6](#t6-ott-9-5975){ref-type="table"}). As to rs863091, a reduced risk of GC associated with the variant genotypes was observed in younger subjects (age \<60 years) (*P*=0.006, adjusted OR =0.58, 95% CI =0.39--0.85) but not in older subjects (*P*=0.725, adjusted OR =0.94, 95% CI =0.66--1.34). In male subjects, the rare genotypes were associated with a decreased risk of GC (*P*=0.025, adjusted OR =0.70, 95% CI =0.51--0.96), whereas the association was not statistically significant in female subjects (*P*=0.482, adjusted OR =0.84, 95% CI =0.50--1.38). We did not find significant association of polymorphism with the GC susceptibility in terms of smoking status and residence. No significant association with GC risks in any stratified analysis was evident in *DACT1* rs17832998 or rs167481.

We also conducted stratified analyses according to tumor differentiation, depth of tumor infiltration, lymph node metastasis, and localization and found no obvious correlations between the variant genotypes and the clinical features of GC ([Tables 7](#t7-ott-9-5975){ref-type="table"}[](#t8-ott-9-5975){ref-type="table"}--[9](#t9-ott-9-5975){ref-type="table"}).

Discussion
==========

This case--control study is the first to evaluate the association between three tag SNPs in *DACT1* genes and the risk of GC in a Chinese Han population. In our findings, the *DACT1* rs863091 SNP was related to a decreased risk of GC, especially in younger subjects (age \<60 years) and male subjects. The results indicate that the T allele of *DACT1* rs863091 may be a protective factor against GC. In the stratified analysis, we identified more prominent protective effect of rs863091 GC variant genotypes in younger subjects (age \<60 years) and males. The difference in age may be related to a weaker immune system in older individuals[@b17-ott-9-5975] and accumulated exposure to environmental carcinogens, but further research is necessary to clarify the mechanism underlying the association between *DACT1* polymorphisms and age. de Martel et al[@b18-ott-9-5975] has reported that males are more likely to suffer from GC compared with females by a ratio of about 2:1, and male cardia cancer rates were two to three times greater than those in women in a Chinese population. We did not find significant association of polymorphism with the GC susceptibility in terms of smoking status. Tobacco smoke is a confirmed independent risk factor for GC,[@b19-ott-9-5975] so the only exception in the characteristics analysis was that smoking was more frequently distributed in GC patients than controls. Whether the association between polymorphisms and GC risk may be masked by the overwhelming effect of accumulated exposure to tobacco carcinogens in smokers needs further research. Our data indicate that *DACT1* polymorphisms may have an important effect on men with GC. However, further studies are needed to confirm these results.

Human *DACT1* gene was located within human genome draft sequence NT_025892.9 (nucleotide position 39378960--39387891 in the forward orientation). Previous studies demonstrated that *DACT1*, a member of DACT family, plays pivotal roles in the regulation of embryogenesis and cancer development. *DACT1* has been considered as a regulator of Wnt signaling through its interplay with Dvl, an important mediator of both the noncanonical and the canonical Wnt pathways. *DACT1* antagonizes Wnt signaling by inducing disheveled (Dvl) degradation via a lysosome inhibitor-sensitive and proteasome inhibitor-insensitive mechanism.[@b8-ott-9-5975],[@b16-ott-9-5975],[@b20-ott-9-5975] *DACT1* also functions as a tumor suppressor through antagonizing the Wnt/b-catenin signaling pathway in breast cancer, hepatocellular cancer, and non-small-cell lung cancer.[@b13-ott-9-5975]--[@b15-ott-9-5975] In addition, as a cytoplasmic protein, *DACT1* interacts and posttranslationally regulates central PCP components Dvl2 and Vangl2 and regulates PCP downstream of the Rac1/JNK cascade. Loss of *Dact1* leads to posterior malformations in mice.[@b9-ott-9-5975]--[@b11-ott-9-5975],[@b20-ott-9-5975] Wang et al[@b12-ott-9-5975] reported that *DACT1* suppresses tumorigenesis in GC through inhibiting NF-κB signaling pathway, and its promoter methylation is significantly associated with tumor aggressiveness. Previously, another study has reported that the methylated CpG site count of *DACT1* promoter may predict the clinical prognosis of GC.[@b21-ott-9-5975] However, there is no report about the association between *DACT1* genetic variation and risk of cancer in the Chinese Han population.

In this study, *DACT1* rs863091 was associated with a significantly decreased GC risk in the Chinese Han population. Moreover, mutational genotypes of *DACT1* rs863091 tend to be upregulated in GC tissues, suggesting a genotype-specific effect of this exon SNP on *DACT1*, thus supporting a protective role for the susceptibility to GC. The C/T polymorphism rs863091 is located in exon 4 of *DACT1* gene, and the polymorphism is synonymous. Increasing evidence shows that synonymous polymorphisms have a significant impact on the efficiency of protein translation, the translated protein levels, as well as affecting splicing processes, stability of mRNA, microRNA binding, and nucleosome formation.[@b22-ott-9-5975],[@b23-ott-9-5975] Synonymous mutations can also influence the accuracy or speed of translation mainly because of the sufficient corresponding transfer RNAs.[@b24-ott-9-5975]--[@b30-ott-9-5975] Moreover, changing of translation rate can impact protein function via folding,[@b31-ott-9-5975] as in most cases folding is executed during translation.[@b32-ott-9-5975] The *DACT1* rs863091 mutation may lead to alterations in *DACT1* structure through changing the translational efficiency, which may regulate the *DACT1* function finally. A preceding study pointed out that the effect of *DACT1* on GC was associated with promoter methylation of *DACT1*.[@b12-ott-9-5975],[@b21-ott-9-5975] Hence, we speculate that alterations in *DACT1* function may affect *DACT1* promoter methylation and may influence the interaction of *DACT1* and Dvl2. Nevertheless, in normal tissues, *DACT1* mRNA expression levels in samples with variant genotypes have no significant differences with wild genotype. The primary explanation for the differential findings between normal and cancer tissues might be the relatively small numbers of samples. The differential observations might also be because *DACT1* is a hinge of the complex network of proteins.[@b9-ott-9-5975]--[@b11-ott-9-5975],[@b20-ott-9-5975] Furthermore, the expression of *DACT1* may alter according to other tumor-related genes or due to differences in downstream targets of the enzyme.[@b12-ott-9-5975] Therefore, we speculate that there are some mechanisms working as triggering information exists in tumor tissues but not in normal tissues. However, these hypotheses should be confirmed by our further studies.

There are several limitations in the study that should be considered. First, because it was a hospital-based case--control study, selection bias could not be avoided. Nonetheless, the genotype distribution of the controls in our study met the Hardy--Weinberg conditions. Second, the relatively small sample size may have led to limit statistical power to detect a slight effect and may have underpowered gene--environment interactions in the stratified analyses. Third, we acquired personal information of subjects such as smoking history by questionnaire. Therefore, the inherent selection bias and information bias were unavoidable, which may have led to insufficient statistical power in stratified analysis of smoking status. Fourth, partial missing clinical information on the subjects, such as data on alcohol consumption, histological types, and The Cancer Genome Atlas classifications, prevented further analysis. Moreover, *Helicobacter pylori* infection is one of independent risk factors of GC. We did not have enough information on *H. pylori* status because it was unethical to perform *H. pylori* tests for every subject, especially for controls. Finally, the study was conducted in the Chinese Han population. Data should be extrapolated to other ethnic groups cautiously.

Conclusion
==========

Our study for the first time demonstrates that the CT/TT genotype of *DACT1* rs863091 polymorphism is significantly associated with a decreased risk of GC in the Chinese Han population, especially in younger individuals and males. The T allele may be a protective factor against GC.
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![Correlation between rs863091 genotypes and expression of *DACT1* mRNA.\
**Notes:** (**A**) Genotype--phenotype correlation for rs863091 and relative expression levels of *DACT1* mRNA in 76 GC tissues. Relative *DACT1* mRNA expression levels were significantly higher for the CT (0.21±0.18), TT (0.28±0.16), and CT + TT genotypes (0.22±0.17) than the CC genotype (0.10±0.12); \**P*\<0.05 and \*\**P*\<0.01. (**B**) Genotype--phenotype correlation for rs863091 and relative expression levels of *DACT1* mRNA in 76 normal gastric tissues. Relative *DACT1* mRNA expression levels were similar among the three groups with rs863091 CC, CT, and TT genotypes.\
**Abbreviations:** *DACT1*, disheveled-binding antagonist of beta-catenin 1; GC, gastric cancer; mRNA, messenger RNA.](ott-9-5975Fig1){#f1-ott-9-5975}

###### 

Information on primers and probes

  SNPs         Primer sequence (5′-3′)      Probe sequence
  ------------ ---------------------------- ---------------------------
  rs863091     F-CACCCTGTAAGGACCAACAAACC    C:FAM-TGTGTCAGAGCCCCG-MGB
  C\>T         R-GCAGACACGCCTGTTTCGA        T:HEX-TGTGTTAGAGCCCCG-MGB
  rs17832998   F-TGCCTCCGACCTTCAGAGTAAG     C:FAM-CATGCTCGGTGTTCC-MGB
  C\>T         R-GGGCTGTACAACTTTGTTCTCCTG   T:HEX-CATGTTCGGTGTTCC-MGB
  rs167481     F-GCACCTTTCACTGGTGGAAA       C:FAM-ATATTCTGATAGCAG-MGB
  C\>T         R-AGACCTACAATATTGGGACAGGA    T:HEX-ATATTTTGATAGCAG-MGB

**Abbreviations:** SNPs, single-nucleotide polymorphisms; FAM, carboxyfluorescein; HEX, hexachloro-fluorescein; MGB, Minor Groove Binder; F, forward; R, reverse.

###### 

Demographic information

  Characteristics                                         Cases (N=602)   Controls (N=602)   *P*-value
  ------------------------------------------------------- --------------- ------------------ -----------
  Age (years)[a](#tfn3-ott-9-5975){ref-type="table-fn"}   60.6±10.7       59.5±12.9          0.087
  Sex, n (%)                                                                                 0.067
   Female                                                 164 (27.2)      193 (32.1)         
   Male                                                   438 (72.8)      409 (67.9)         
  Hypertension, n (%)                                                                        0.569
   No                                                     430 (71.4)      421 (69.9)         
   Yes                                                    172 (28.6)      181 (30.1)         
  Diabetes, n (%)                                                                            0.174
   No                                                     541 (89.9)      526 (87.4)         
   Yes                                                    61 (10.1)       76 (12.6)          
  Smoking, n (%)                                                                             **0.012**
   Never                                                  474 (78.7)      508 (84.4)         
   Ever                                                   128 (21.3)      94 (15.6)          
  Residence, n (%)                                                                           0.116
   Rural                                                  358 (52.6)      331 (48.0)         
   Urban                                                  244 (47.4)      271 (52.0)         
  Tumor differentiation, n (%)                                                               
   Well                                                   34 (5.6)                           
   Moderate                                               122 (20.3)                         
   Poor                                                   446 (74.1)                         
  Depth of tumor infiltration, n (%)                                                         
   T1                                                     90 (14.9)                          
   T2                                                     68 (11.3)                          
   T3                                                     270 (44.9)                         
   T4                                                     174 (28.9)                         
  Lymph node metastasis, n (%)                                                               
   Negative                                               196 (32.6)                         
   Positive                                               406 (67.4)                         
  Localization, n (%)                                                                        
   Cardia                                                 265 (44.0)                         
   Noncardia                                              337 (56.0)                         

**Notes:** The bold value indicates statistically significant data.

Mean ± SD.

###### 

Association between *DACT1* gene polymorphisms and risk of gastric cancer

  Genotypes    Cases, n (%)   Controls, n (%)   Crude OR (95% CI)       *P*-value   Adjusted OR (95% CI)[a](#tfn5-ott-9-5975){ref-type="table-fn"}   *P*-value
  ------------ -------------- ----------------- ----------------------- ----------- ---------------------------------------------------------------- -----------
  Overall      602            602                                                                                                                    
  rs863091                                                                                                                                           
   CC          463 (76.9)     430 (71.4)        1                                   1                                                                
   CT          131 (21.8)     150 (24.9)        0.81 (0.62--1.06)       0.127       0.80 (0.61--1.05)                                                0.101
   TT          8 (1.3)        22 (3.7)          **0.34 (0.15--0.77)**   **0.009**   **0.34 (0.15--0.78)**                                            **0.011**
   CT + TT     139 (23.1)     172 (28.6)        **0.75 (0.58--0.97)**   **0.030**   **0.74 (0.57--0.97)**                                            **0.026**
  Allelic                                                                                                                                            
   C           1,057 (87.8)   1,010 (83.9)      **0.72 (0.58--0.91)**   **0.007**                                                                    
   T           147 (12.2)     194 (16.1)                                                                                                             
   HWE                        0.055                                                                                                                  
  rs17832998                                                                                                                                         
   CC          365 (62.6)     377 (62.6)        1                                   1                                                                
   CT          218 (36.2)     203 (33.7)        1.11 (0.87--1.41)       0.396       1.11 (0.88--1.42)                                                0.381
   TT          19 (3.2)       22 (3.7)          0.89 (0.48--1.68)       0.722       0.88 (0.47--1.67)                                                0.701
   CT + TT     237 (39.4)     225 (37.4)        1.09 (0.86--1.37)       0.477       1.09 (0.86--1.38)                                                0.458
  Allelic                                                                                                                                            
   C           948 (78.7)     957 (79.5)        1.05 (0.86--1.27)       0.688                                                                        
   T           256 (21.3)     247 (20.5)                                                                                                             
   HWE                        0.404                                                                                                                  
  rs167481                                                                                                                                           
   CC          161 (26.7)     176 (29.2)        1                                   1                                                                
   CT          301 (50.0)     294 (48.9)        1.12 (0.86--1.46)       0.409       1.11 (0.85--1.45)                                                0.464
   TT          140 (23.3)     132 (21.9)        1.16 (0.84--1.60)       0.365       1.13 (0.82--1.57)                                                0.447
   CT + TT     441 (73.3)     426 (70.8)        1.13 (0.88--1.46)       0.336       1.12 (0.87--1.45)                                                0.371
  Allelic                                                                                                                                            
   C           623 (51.7)     646 (53.7)        1.08 (0.92--1.27)       0.369                                                                        
   T           581 (48.3)     558 (46.3)                                                                                                             
   HWE                        0.659                                                                                                                  

**Notes:** The bold values indicate statistically significant data.

Adjusted for age, sex, smoking status, residence, hypertension, and diabetes.

**Abbreviations:** CI, confidence interval; *DACT1*, disheveled-binding antagonist of beta-catenin 1; HWE, Hardy--Weinberg equilibrium; OR, odds ratio.

###### 

Stratified analyses for *DACT1* rs863091 genotypes in cases and controls

  Variables           CT + TT vs CC for rs863091   Allelic ORs and 95% CIs for rs863091                           
  ------------------- ---------------------------- -------------------------------------- ----------------------- -----------
  Age (years), mean                                                                                               
   ≥60                85 (14.1)/256 (42.5)         80 (13.3)/229 (38.0)                   0.94 (0.66--1.34)       0.725
   \<60               54 (9.0)/207 (34.4)          92 (15.3)/201 (33.4)                   **0.58 (0.39--0.85)**   **0.006**
  Sex                                                                                                             
   Females            36 (6.0)/128 (21.3)          48 (8.0)/145 (24.1)                    0.84 (0.50--1.38)       0.482
   Males              103 (17.1)/335 (55.6)        124 (20.6)/285 (47.3)                  **0.70 (0.51--0.96)**   **0.025**
  Smoking status                                                                                                  
   Smokers            26 (4.3)/102 (16.9)          29 (4.8)/65 (10.8)                     0.60 (0.32--1.14)       0.119
   Nonsmokers         113 (18.8)/361 (60.0)        143 (23.8)/365 (60.6)                  0.79 (0.59--1.05)       0.100
  Residence                                                                                                       
   Rural              90 (15.0)/268 (44.5)         99 (16.4)/232 (38.5)                   0.78 (0.56--1.10)       0.157
   Urban              49 (8.1)/195 (32.4)          73 (12.1)/198 (32.9)                   0.69 (0.46--1.04)       0.079

**Notes:** The bold values indicate statistically significant data.

Adjusted for age, sex, smoking status, residence, hypertension, and diabetes. CT+TT vs CC was expressed as CT+TT/CC.

**Abbreviations:** CI, confidence interval; *DACT1*, disheveled-binding antagonist of beta-catenin 1; OR, odds ratio.

###### 

Stratified analyses for *DACT1* rs17832998 genotypes in cases and controls

  Variables           CT + TT vs CC for rs17832998   Allelic ORs and 95% CIs for rs17832998                       
  ------------------- ------------------------------ ---------------------------------------- ------------------- -------
  Age (years), mean                                                                                               
   ≥60                134 (22.3)/207 (34.4)          123 (20.4)/186 (30.9)                    0.98 (0.71--1.36)   0.924
   \<160              103 (17.1)/158 (26.2)          102 (17.0)/191 (31.7)                    1.23 (0.87--1.75)   0.237
  Sex                                                                                                             
   Females            53 (8.8)/111 (18.4)            75 (12.5)/118 (19.6)                     0.74 (0.47--1.15)   0.173
   Males              184 (30.6)/254 (42.2)          150 (24.9)/259 (43.0)                    1.26 (0.95--1.68)   0.105
  Smoking status                                                                                                  
   Smokers            45 (7.5)/83 (13.8)             33 (5.5)/61 (10.1)                       0.95 (0.53--1.70)   0.861
   Nonsmokers         192 (31.9)/282 (46.8)          192 (31.9)/316 (52.5)                    1.10 (0.85--1.43)   0.468
  Residence                                                                                                       
   Rural              139 (23.1)/219 (36.4)          114 (18.9)/217 (36.1)                    1.21 (0.89--1.66)   0.227
   Urban              98 (16.3)/146 (24.2)           111 (18.4)/160 (26.6)                    0.95 (0.66--1.35)   0.758

**Notes:**

Adjusted for age, sex, smoking status, residence, hypertension, and diabetes. CT+TT vs CC was expressed as CT+TT/CC.

**Abbreviations:** CI, confidence interval; *DACT1*, disheveled-binding antagonist of beta-catenin 1; OR, odds ratio.

###### 

Stratified analyses for *DACT1* rs167481 genotypes in cases and controls

  Variables           CT + TT vs CC for rs167481   Allelic ORs and 95% CIs for rs167481                       
  ------------------- ---------------------------- -------------------------------------- ------------------- -------
  Age (years), mean                                                                                           
   ≥60                248 (41.2)/93 (15.4)         214 (35.5)/95 (15.8)                   1.14 (0.80--1.61)   0.465
   \<60               193 (32.1)/68 (11.3)         212 (35.2)/81 (13.5)                   1.06 (0.73--1.55)   0.757
  Sex                                                                                                         
   Females            119 (19.8)/45 (7.5)          138 (22.9)/55 (9.1)                    1.03 (0.64--1.64)   0.917
   Males              322 (53.4)/116 (19.3)        288 (47.9)/121 (20.1)                  1.15 (0.85--1.56)   0.377
  Smoking status                                                                                              
   Smokers            95 (15.8)/33 (5.5)           65 (10.8)/29 (4.8)                     1.29 (0.70--2.36)   0.413
   Nonsmokers         346 (57.5)/128 (21.2)        361 (60.0)/147 (24.4)                  1.09 (0.83--1.45)   0.530
  Residence                                                                                                   
   Rural              257 (42.7)/101 (16.8)        241 (40.0)/90 (15.0)                   0.94 (0.67--1.31)   0.702
   Urban              184 (30.5)/60 (10.0)         185 (30.7)/86 (14.3)                   1.46 (0.99--2.16)   0.059

**Notes:**

Adjusted for age, sex, smoking status, residence, hypertension, and diabetes. CT+TT vs CC was expressed as CT+TT/CC.

**Abbreviations:** CI, confidence interval; *DACT1*, disheveled-binding antagonist of beta-catenin 1; OR, odds ratio.

###### 

Associations between *DACT1* rs863091 genotypes and clinicopathologic characteristics of gastric cancer

  Variables                     CT + TT, CC for rs863091   Allelic ORs and 95% CIs for rs863091                       
  ----------------------------- -------------------------- -------------------------------------- ------------------- -------
  Tumor differentiation                                                                                               
   Well                         7                          27                                     1                   
   Moderate                     24                         98                                     0.91 (0.33--2.54)   0.857
   Poor                         108                        338                                    1.21 (0.51--2.89)   0.661
  Depth of tumor infiltration                                                                                         
   T1                           17                         73                                     1                   
   T2                           21                         47                                     1.85 (0.85--4.00)   0.119
   T3                           52                         218                                    1.05 (0.57--1.94)   0.881
   T4                           49                         125                                    1.64 (0.87--3.10)   0.128
  Lymph node metastasis                                                                                               
   Negative                     44                         152                                    1                   
   Positive                     95                         311                                    1.07 (0.71--1.62)   0.738
  Localization                                                                                                        
   Cardia                       56                         209                                    1                   
   Noncardia                    83                         254                                    1.30 (0.88--1.93)   0.188

**Note:**

Adjusted for age, sex, smoking status, residence, hypertension, and diabetes.

**Abbreviations:** CI, confidence interval; *DACT1*, disheveled-binding antagonist of beta-catenin 1; OR, odds ratio.

###### 

Associations between *DACT1* rs17832998 genotypes and clinicopathologic characteristics of gastric cancer

  Variables                     CT + TT, CC for rs17832998   Allelic ORs and 95% CIs for rs17832998                       
  ----------------------------- ---------------------------- ---------------------------------------- ------------------- -------
  Tumor differentiation                                                                                                   
   Well                         12                           22                                       1                   
   Moderate                     39                           83                                       0.71 (0.29--1.75)   0.458
   Poor                         186                          260                                      1.43 (0.68--3.01)   0.341
  Depth of tumor infiltration                                                                                             
   T1                           31                           59                                       1                   
   T2                           30                           38                                       1.39 (0.70--2.73)   0.347
   T3                           105                          165                                      1.28 (0.76--2.13)   0.352
   T4                           71                           103                                      1.36 (0.77--2.39)   0.286
  Lymph node metastasis                                                                                                   
   Negative                     74                           122                                      1                   
   Positive                     163                          243                                      1.12 (0.79--1.60)   0.532
  Localization                                                                                                            
   Cardia                       106                          159                                      1                   
   Noncardia                    131                          206                                      0.97 (0.69--1.35)   0.840

**Note:**

Adjusted for age, sex, smoking status, residence, hypertension, and diabetes.

**Abbreviations:** CI, confidence interval; *DACT1*, disheveled-binding antagonist of beta-catenin 1; OR, odds ratio.

###### 

Associations between *DACT1* rs167481 genotypes and clinicopathologic characteristics of gastric cancer

  Variables                     CT + TT, CC for rs167481   Allelic ORs and 95% CIs for rs167481                       
  ----------------------------- -------------------------- -------------------------------------- ------------------- -------
  Tumor differentiation                                                                                               
   Well                         22                         12                                     1                   
   Moderate                     91                         31                                     2.08 (0.86--5.06)   0.105
   Poor                         328                        118                                    1.43 (0.68--3.00)   0.345
  Depth of tumor infiltration                                                                                         
   T1                           67                         23                                     1                   
   T2                           49                         19                                     1.00 (0.48--2.11)   0.994
   T3                           206                        64                                     1.10 (0.63--1.92)   0.742
   T4                           119                        55                                     0.79 (0.44--1.41)   0.426
  Lymph node metastasis                                                                                               
   Negative                     139                        57                                     1                   
   Positive                     302                        104                                    1.18 (0.81--1.73)   0.369
  Localization                                                                                                        
   Cardia                       202                        63                                     1                   
   Noncardia                    239                        98                                     0.75 (0.52--1.09)   0.130

**Note:**

Adjusted for age, sex, smoking status, residence, hypertension, and diabetes.

**Abbreviations:** CI, confidence interval; *DACT1*, disheveled-binding antagonist of beta-catenin 1; OR, odds ratio.

[^1]: These authors contributed equally to this work
